Нервно-мышечные болезни

Расширенный поиск

Положительное влияние ацетил-L-карнитина на болевой синдром, регенерацию нервов и вибрационное чувство у пациентов с хронической диабетической нейропатией. Анализ результатов двух рандомизированных плацебоконтролируемых исследований

Полный текст:

Об авторах

Anders A.F. Sima
Departments of Pathology and Neurology, Wayne State University, Detroit, MI

Menotti Calvani
Sigma-Tau spA, Pomezia, Rome, Italy

Munish Mehra
Medifacts International, Rockville, MD

Antonino Amato
Sigma-Tau Research, Gaithersburg, MD

Список литературы

1. Sugimoto K., Murakawa Y., Sima A.A.F. Diabetic neuropathy: a continuing enigma. Diabetes Metab Res Rev2000;16:408–33.

2. Sima A.A.F. New insights into the metabolic and molecular basis for diabetic neuropathy. Cell Mol Life Sci 2003;60:2445–64.

3. Dyck P.J., Thomas P.K. Diabetic polyneuropathy. In: Diabetic Neuropathy. Philadelphia: W.B. Saunders, 1999; p. 239–406.

4. Sima A.A.F. Diabetic neuropathy: pathogenetic background, current and future therapies. Expert Rev Neurotherapeutics 2001;1:225–38.

5. Fagius J., Brattberg A., Jameson S., Berne C. Limited benefits of treatment of diabetic polyneuropathy with an aldose reductase inhibitor: a 24-wk controlled trial. Diabetologia 1985;28:323–9.

6. Sima A.A.F., Bril V., Nathaniel V. et al. Regeneration and repair of myelinated fibers in sural nerve biopsies from patients with diabetic neuropathy treated with an aldose reductase inhibitor. N Engl J Med 1988;319: 548–55.

7. Boulton A.J.M., Levin S., Comstock J.A. A multicenter trial of the aldose reductase inhibitor tolrestat, in patients with symptomatic diabetic neuropathy. Diabetologia 1990;33:431–7.

8. Macleod A.F., Boulton A.J.M., Owens D.R. et al. A multicenter trial of the aldose reductase inhibitor in patients with symptomatic diabetic peripheral neuropathy. Diabetes Metab 1992;8: 14 –20.

9. Pfeifer M.A., Schumer M.P., Gelber D.A. Aldose reductase inhibitors: the end of an era or the need for different trial design. Diabetes 1997;46:582–9.

10. Ziegler D., Hanefeld M., Ruhnau K.-J. et al. Treatment of symptomatic diabetic polyneuropathy with the anti-oxidant α-lipoic acid. Diabetes Care 1999;22:1296–301.

11. Scarpini E., Doneda P., Pizzul S. et al. L-carnitine and acetyl-L-carnitine in human nerves from normal and diabetic subjects. J Peripher Nerv Syst 1996;1:157–63.

12. Ido Y., McHowat J., Chang K.C. et al. Neural dysfunction and metabolic imbalances in diabetic rats: prevention by acetyl-Lcarnitine. Diabetes 1994;43:1469–77.

13. Sima A.A., Ristic H., Merry A. et al. The primary preventive and secondary interventionary effects of acetyl-L-carnitine on diabetic neuropathy in the bio-breeding Worcester rat. J Clin Invest 1996;97:1900–7.

14. Williamson J.R., Arrigoni-Martelli E. The role of glucose-induced metabolic hypoxia and imbalances in carnitine metabolism in mediating diabetes-induced vascular dysfunction. Int J Clin Pharmacol Res 1992;12:247–52.

15. Stevens M.J., Lattimer S.A., Feldman E.L. t al. Acetyl-L-carnitine deficiency as a cause of altered nerve myo-inositol content, Na-/K--ATPase activity and motor conduction velocity in the streptocin diabetic rat. Metabolism 1996;45:865–72.

16. Lowitt S., Malone J.I., Salem A.F. et al. Acetyl-L-carnitine corrects the altered peripheral nerve function of experimental diabetes. Metabolism 1995;44:677–80.

17. Scarpini E., Sacilotto G., Baron P. et al. Effect of acetyl-L-carnitine in the treatment of painful peripheral neuropathies in HIVpatients. J Peripher Nerv Syst 1997;2:250 –2.

18. Onofrj M., Fulgente T., Melchionda D. et al. L-acetyl-carnitine as a new therapeutic approach for peripheral neuropathies with pain. Int J Clin Pharmacol Res 15:9–15.

19. Quatraro A., Roca P., Donzella C. et al. Acetyl-L-carnitine for symptomatic diabetic neuropathy. Diabetologia 1995;38:123.

20. Report and recommendations of the San Antonio Conference on diabetic neuropathy. Diabetes 1988;37:1000–4.

21. Laudadio C., Sima A.A.F. Design of controlled clinical trials for diabetic polyneuropathy. Semin Neurol 1996;16:187–91.

22. Sima A.A.F., Blaivas M. Peripheral neuropathies. In Neuropathology: The Diagnostic Approach. Garcia J., McKeevar P., Sima A.A.F., Eds. Philadelphia: Mosby, 1997, p. 765–809.

23. O’Brien P.C. Procedures for comparing samples with multiple endpoints. Biometrics 1984;40:1079–87.

24. Arezzo J.C., Schaumburg H.H., Laudadio C. The Vibratron: a simple device for quantitative evaluation of tactile/vibratory sense (Abstract). Neurology 1985;35 (Suppl. 1):169.

25. Greene D.A., Arezzo J.C., Brown M.D., the Zenarestat Study Group: Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Neurology 1999;53:580–91.

26. Bohning D. Computer-Assisted Analysis of Mixtures and Applications. New York: Chapman and Hall/CRC, 1999.

27. Burchiel K.J., Russel L.C., Lee R.P., Sima A.A.F. Spontaneous activity of primary afferent neurons in diabetic BB-Wistar rats: a possible mechanism of chronic pain. Diabetes 1985;34:1210–3.

28. Dyck P.K., Lambert E.H., O’Brien P.C. Pain in peripheral neuropathy related to rate and kind of fiber degeneration. Neurology 1976;26:466–71.

29. Kapur D. Neuropathic pain and diabetes. Diabetes Metab Res Rev 2003;19:9–15.

30. Singleton J.R., Smith A.G., Bromberg M.B. Increased prevalence of impaired glucose tolerance in patients with painful sensory neuropathy. Diabetes Care 2001;24:1448–53.

31. Murakawa Y., Zhang W., Pierson C.R. et al. Impaired glucose tolerance and insulinopenia in the GK-rat causes peripheral neuropathy. Diabetes Metab Res Rev 2002;18:473–83.

32. Kamiya H., Zhang W., Sima A.A.F. C-peptide prevents nociceptive sensory neuropathy in type 1 diabetes. Ann Neurol. In press.

33. Chiechio S., Caricasole A., Barletta E. et al. L-acetylcarnitine induces analgesia by selectively up-regulating mGlu2 metabotropic glutamate receptors. Molecul Pharm 2002;61:1– 8.

34. Tomlinson D.R., Fernyhough P., Diemal L.T. Role of neurotrophins in diabetic neuropathy and treatment with nerve growth factor. Diabetes 1997;46 (Suppl 2):543–9.

35. DiGiulio A.M., Gorio A., Bertelli A. et al. Acetyl-L-carnitine prevents substance P loss in the sciatic nerve and lumbar spinal cord of diabetic animals. Int J Clin Pharmacol Res 1992;12:243–6.

36. Woolf C.J., Mannison R.J. Neuropathic pain: etiology, symptoms, mechanisms and management. Lancet 1999;353:1959–64.

37. Woolf C.J., Shortland P., Coggeshall R.E. Peripheral nerve injury triggers central sprouting of myelinated afferents. Nature 1992;355:75–8.

38. Sima A.A.F., Kamiya H. Insulin, C-peptide, and diabetic neuropathy. Sci Med 2004;10:308–19.


Для цитирования:

A.F. Sima A., Calvani M., Mehra M., Amato A. Положительное влияние ацетил-L-карнитина на болевой синдром, регенерацию нервов и вибрационное чувство у пациентов с хронической диабетической нейропатией. Анализ результатов двух рандомизированных плацебоконтролируемых исследований. Нервно-мышечные болезни. 2014;(3):6-12.

For citation:

A.F. Sima A., Calvani M., Mehra M., Amato A. Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory perception in patients with chronic diabetic neuropathy. Neuromuscular Diseases. 2014;(3):6-12. (In Russ.)

Просмотров: 1113

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.

ISSN 2222-8721 (Print)
ISSN 2413-0443 (Online)